Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664310 | 0.91 | CFTR (0.46) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664143 | 0.91 | POLB (0.46) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664373 | 0.91 | POLB (0.46) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664435 | 0.91 | RHOC (0.43) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664426 | 0.90 | POLB (0.42) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664398 | 0.90 | NPC1 (0.46) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664403 | 0.90 | L3MBTL1 (0.46) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664397 | 0.89 | NPC1 (0.48) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664354 | 0.89 | POLB (0.43) | NPC1POLBGAAMAPTTDP1 | |
| SCHEMBL13664487 | 0.89 | NPC1 (0.43) | NPC1POLBGAAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | NPC1 2164/4885TRPV1 397/4885POLB 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.